Conformis, Inc. (CFMS) Analysts See $-0.21 EPS

July 11, 2018 - By Billy Entrekin

Conformis, Inc. (NASDAQ:CFMS) Logo

Analysts expect Conformis, Inc. (NASDAQ:CFMS) to report $-0.21 EPS on August, 2.They anticipate $0.07 EPS change or 25.00 % from last quarter’s $-0.28 EPS. After having $-0.22 EPS previously, Conformis, Inc.’s analysts see -4.55 % EPS growth. The stock decreased 5.13% or $0.06 during the last trading session, reaching $1.11. About 403,602 shares traded. Conformis, Inc. (NASDAQ:CFMS) has declined 70.00% since July 12, 2017 and is downtrending. It has underperformed by 82.57% the S&P500.

Conformis, Inc. (NASDAQ:CFMS) Ratings Coverage

Among 2 analysts covering ConforMIS (NASDAQ:CFMS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ConforMIS had 3 analyst reports since February 8, 2018 according to SRatingsIntel. The stock of Conformis, Inc. (NASDAQ:CFMS) earned “Hold” rating by Canaccord Genuity on Thursday, February 8. Canaccord Genuity upgraded Conformis, Inc. (NASDAQ:CFMS) on Tuesday, April 10 to “Buy” rating.

ConforMIS, Inc., a medical technology company, develops, makes, and sells customized joint replacement implants. The company has market cap of $67.61 million. The firm offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It currently has negative earnings. It is also developing iTotal Hip, a customized total hip replacement implant.

Another recent and important Conformis, Inc. (NASDAQ:CFMS) news was published by which published an article titled: “Peer Reviewed Results: Conformis Patient Specific iTotal CR Achieves Better Rotational Alignment and Tibial Fit …” on June 25, 2018.

Conformis, Inc. (NASDAQ:CFMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.